Multiple Myeloma

MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma

By

Susan Moench, PhD, PA-C

Publish Date January 15, 2020

Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.

Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early

By

Susan Moench, PhD, PA-C

Publish Date January 13, 2020

Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.

Antibiotic Prophylaxis Shown to Reduce Infection Risk for Patients With Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

Publish Date January 8, 2020

Prophylactic antibiotics trended toward reducing infection risk at 3 months if given in first 2 to 3 months after MM diagnosis; however, it had no effect on mortality rates.

Modified Bortezomib, Lenalidomide, Dexamethasone Induction Regimen Efficacious, Tolerable for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

By

Vicki Moore, PhD

Publish Date December 17, 2019

A modified induction protocol (VRd lite) demonstrated high efficacy with better tolerability in patients with NDMM who are eligible for ASCT.

Tandem Transplant Strategies Associated With Higher Progression-Free Survival in Patients With Multiple Myeloma

By

Tiffany Garbutt, PhD

Publish Date December 8, 2019

This retrospective analysis compared auto-HSCT and allo-HSCT with tandem auto-HSCT and auto-allo-HSCT to determine which strategy provided better PFS and OS for patients with multiple myeloma.